Key result
DOAC exposure during pregnancy shows no clear association with adverse perinatal outcomes.
Why the study?
Data on the safety of direct oral anticoagulants during pregnancy remain limited.
What are the perinatal safety outcomes in pregnancies exposed to direct oral anticoagulants?
What are the perinatal safety outcomes in pregnancies exposed to direct oral anticoagulants?
In the French pharmacovigilance database, adverse perinatal outcomes in DOAC-exposed pregnancies could not be clearly attributed to the drugs due to frequent confounding factors, highlighting the need for systematic reporting.
Answers are grounded in this paper and cite their sources.
DOAC use in pregnancy warrants caution amid unclear risks; leaves open the need for systematic safety registries.
Essentials• Data on the safety of direct oral anticoagulants (DOAC) during pregnancy remain limited.• DOAC-exposed pregnancies were identified in the French national pharmacovigilance database.• Adverse outcomes could not be clearly attributed to DOACs due to frequent confounding factors.• Systematic reporting of DOAC exposure in pregnancy is needed to assess maternal and fetal risks.
No takes yet. Share an insight, caveat, or question.
Fijean et al. (2026) studied this question. Direct oral anticoagulant exposure during pregnancy could not be clearly linked to adverse perinatal outcomes due to frequent confounding factors in the French pharmacovigilance database.
Synapse has enriched 10 related papers. Consider them for comparative context: